Global
Antibody Drug Conjugates
Unlock the most comprehensive insights into the rapidly evolving Antibody Drug Conjugates (ADCs) landscape with our latest market intelligence report. It profiles 550+ drug developers and tracks 1,200+ active ADC molecules across clinical and preclinical pipelines, platforms, targets, payloads, and technologies. If you’re working in oncology, biologics, or drug development strategy, this is built to inform your next decision.
Explore cutting-edge technologies, key patents, and clinical advancements driving the next generation of targeted therapeutics. Whether you’re in drug discovery, business development or in competitive intelligence, this report is your essential guide to the future of Antibody Drug Conjugates therapies.
providing intelligence at fingertips
23 Global Countries’ Covered
ADCs Drug Developers Insights
Individual Drug Mechanism of Action & Drug Target
Covers complete Emerging Drug Targets Details with Emerging Technologies
725 pages full of Insights
Antibody Drug Conjugates (ADCs) | Comprehensive Insights |
|---|---|
Market Landscape | Forecasting the Future: ADC Market Outlook to 2030. Expected Market Growth & Investment Trends | Pipeline Highlights : Potential Approvals by 2030. |
Technology Development Landscape | Over 150+ Proprietary ADC Conjugation, Payload & Linker Technologies Details Developers | Tech. Name | Conjugation Chemistry | Description | Partners |
Drug Recent Patents / IP Landscape | Drug Developer’s Exclusive ADC Linked Patents Details 455 ADC Linked Patents Description with Patent Number and Date |
Target Development Landscape | Insights on TOP 50 Emerging Targets Diversity in ADC Space. Grouped in Five Major Clusters based on their Clinical Maturity and Promise |
Clinical Pipeline Landscape | Clinical Phase wise (III, II & I) Antibody Drug Conjugates in Clinical Development. ADC | Developer/Partners | Target | Payload | Linker | DAR | Conjugation Technology |
NCT Number | Key Indications | Expected Launch. |
Deals, Funding & Alliance Landscape | Year wise Insights on Drug Development Funding & Deals in ADC Over 400+ ADC Exclusive Deals and Funding Details. |
How Intelligence offered by OmicsX is different from other resources
Better Than Others
Comparisons | Global Antibody Drug Conjugates 2025 | Other Intelligence Sources |
|---|---|---|
ADC Drug Developers (NME only) | 550+ Active Companies (Well Funded with clear defined clinical & early stage Pipeline) | 350-450 Companies (with many inactive and other domain companies) |
Active ADCs in Development | Tracks 1200+ Antibody Drug Conjugates (NME) in Active Development(Complete Clinical & Preclinical Pipeline with indications, Drug Targets and Mechanism of Action) | 400 – 600 ADC (NME) Drugs (mainly focuses on Clinical Stage molecules with Biosimilar Data) |
Bio-Partnering Details | 400+ ADC exclusive Deals complete details.(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation) | Limited to Database / Resource Subscribed to.(Also it may require mapping of events between two or more different resources and filtering ADC Linked Deals). |
Single Step Connect | Over 1500+ Key Decision Makers in 550+ Companieswith valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available) | No Customized Solution Available in Market(Needs months of hard team work to prepare authentic business development tool. |
Trusted by
